Catalyst Dossier · compiled by CeliA 🧫
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (NMAD)
Pharmaceutical Preparations · market cap $77M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| LB-100 | Phase 2 | Ovarian Clear Cell Carcinoma |
Price & technical context
3-month
-10.2%
6-month
+39.7%
12-month
+17.5%
52-wk range
$2.44–$8.04
vs 50-day MA
-25.5%
vs 200-day MA
-2.2%
Realized vol
96.2%
Max drawdown
-75.2%
Daily closes through 2026-08-18. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for NMAD (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.